Literature DB >> 33479659

Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate as an HIV-1 replication inhibitor.

Jeanne Fichez1, Cathia Soulie2, Laurent Le Corre1, Sophie Sayon2, Stéphane Priet3,4, Karine Alvarez3, Olivier Delelis5, Patrick Gizzi6, Guillaume Prestat1, Christine Gravier-Pelletier1, Anne-Geneviève Marcelin2, Vincent Calvez2, Patricia Busca1.   

Abstract

Inspired by the antiviral activity of known pyrazole-based HIV inhibitors, we screened our in-house library of pyrazole-based compounds to evaluate their in cellulo activity against HIV-1 replication. Two hits with very similar structures appeared from single and multiple-round infection assays to be non-toxic and active in a dose-dependent manner. Chemical expansion of their series allowed an in-depth and consistent structure-activity-relationship study (SAR) to be built. Further ADME evaluation led to the selection of 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate with an advantageous pharmacokinetic profile. Finally, examination of its mode of action revealed that this compound does not belong to the three main classes of anti-HIV drugs, a feature of prime interest in the context of viral resistance. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479659      PMCID: PMC7593888          DOI: 10.1039/d0md00025f

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  19 in total

Review 1.  Toxicity of antiretroviral therapy and implications for drug development.

Authors:  Andrew Carr
Journal:  Nat Rev Drug Discov       Date:  2003-08       Impact factor: 84.694

Review 2.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

Review 3.  Lersivirine - a new drug for HIV infection therapy.

Authors:  Martin Platten; Gerd Fätkenheuer
Journal:  Expert Opin Investig Drugs       Date:  2013-10-16       Impact factor: 6.206

4.  International AIDS Society global scientific strategy: towards an HIV cure 2016.

Authors:  Steven G Deeks; Sharon R Lewin; Anna Laura Ross; Jintanat Ananworanich; Monsef Benkirane; Paula Cannon; Nicolas Chomont; Daniel Douek; Jeffrey D Lifson; Ying-Ru Lo; Daniel Kuritzkes; David Margolis; John Mellors; Deborah Persaud; Joseph D Tucker; Françoise Barre-Sinoussi; Galit Alter; Judith Auerbach; Brigitte Autran; Dan H Barouch; Georg Behrens; Marina Cavazzana; Zhiwei Chen; Éric A Cohen; Giulio Maria Corbelli; Serge Eholié; Nir Eyal; Sarah Fidler; Laurindo Garcia; Cynthia Grossman; Gail Henderson; Timothy J Henrich; Richard Jefferys; Hans-Peter Kiem; Joseph McCune; Keymanthri Moodley; Peter A Newman; Monique Nijhuis; Moses Supercharger Nsubuga; Melanie Ott; Sarah Palmer; Douglas Richman; Asier Saez-Cirion; Matthew Sharp; Janet Siliciano; Guido Silvestri; Jerome Singh; Bruno Spire; Jeffrey Taylor; Martin Tolstrup; Susana Valente; Jan van Lunzen; Rochelle Walensky; Ira Wilson; Jerome Zack
Journal:  Nat Med       Date:  2016-07-11       Impact factor: 53.440

Review 5.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

6.  Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.

Authors:  M J Genin; C Biles; B J Keiser; S M Poppe; S M Swaney; W G Tarpley; Y Yagi; D L Romero
Journal:  J Med Chem       Date:  2000-03-09       Impact factor: 7.446

7.  CROI 2018: Advances in Antiretroviral Therapy.

Authors:  Hong-Van Tieu; Barbara S Taylor; Joyce Jones; Timothy J Wilkin
Journal:  Top Antivir Med       Date:  2018-05

Review 8.  Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients - a systematic review.

Authors:  T Mathes; D Pieper; S-L Antoine; M Eikermann
Journal:  HIV Med       Date:  2013-06-17       Impact factor: 3.180

Review 9.  Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.

Authors:  Luis Menéndez-Arias
Journal:  Antiviral Res       Date:  2013-02-08       Impact factor: 5.970

10.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Authors:  Stéphane Hué; Robert J Gifford; David Dunn; Esther Fernhill; Deenan Pillay
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

View more
  2 in total

1.  Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.

Authors:  Shasank S Swain; Satya R Singh; Alaka Sahoo; Pritam Kumar Panda; Tahziba Hussain; Sanghamitra Pati
Journal:  Proteins       Date:  2022-04-13

2.  High-Pressure Metal-Free Catalyzed One-Pot Two-Component Synthetic Approach for New 5-Arylazopyrazolo[3,4-b]Pyridine Derivatives.

Authors:  AbdElAziz A Nayl; Hamada Mohamed Ibrahim; Kamal M Dawood; Wael A A Arafa; Ahmed I Abd-Elhamid; Ismail M Ahmed; Mohamed A Abdelgawad; Hazim M Ali; Ibrahim Hotan Alsohaimi; Ashraf A Aly; Stefan Bräse; Asmaa Kamal Mourad
Journal:  Molecules       Date:  2022-09-27       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.